OSR Health Subsidiary Vaximm Completes Analysis From Two Clinical Studies Evaluating VXM01 In Patients With Recurrent Glioblastoma; Data Expected To Be Submitted For Publication In The Coming Months
OSR Health, Inc. (NASDAQ:OSRH) today announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial
A company finished testing a new medicine for a serious brain cancer and will share those results with doctors soon. When a company completes important research and plans to publish it, that's a sign they're making progress on something real.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.